Navigation Links
2nd ESMO symposium on soft tissue carcinomas and GIST
Date:5/12/2008

Experts in treating a rare group of cancers that affect tissues such as muscle, fat, nerves and the gastrointestinal wall are meeting in Milan, Italy on 13-14 May to discuss the latest information on how these diseases develop and potential new avenues for therapy.

The 2nd Symposium on Sarcoma and GIST (Gastrointestinal Stromal Tumors) organized by the European Society for Medical Oncology (ESMO), will include sessions on the genetics of sarcomas, on understanding how drug resistance develops and possibilities for new treatment options.

There will be a particular focus on how scientists and clinicians can work together to develop new treatments, including molecular targeted therapies. The theme of the meeting is 'Insights at the crossroads of molecular biology, pathology and clinic.'

"Sarcomas are relatively rare, but they are serving as a model for the way new molecular targeted therapies are being introduced into clinical practice," said co-chair of the event Dr. Paolo G. Casali, Head of the Sarcoma Medical Treatment Unit at the Milan Istituto Nazionale Tumori and Chair of the ESMO Sarcoma Working Group. "This challenges our ability to combine information from as diverse areas as biology, pathology and the clinic to achieve better results for patients."

"The molecular and pathological bases represent extremely valuable diagnostic and prognostic information for the proper treatment of this disease, although the way we can exploit all these data in the clinic is still to be defined properly," said co-chair Dr. Paolo Dei Tos, Director of the Pathology Unit of the Regional Hospital of Treviso, Italy.

Sarcomas are cancers of the connective or supportive tissues, such as muscles, tendons, ligaments, nerves, fat and blood vessels, therefore they can arise everywhere in the body, although they are rare. Sarcomas are also different to the much more frequent carcinomas of the breast, colon, lung, and others.

Around
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
3. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
4. XShares Supports Parkinsons Disease Foundation 50th Anniversary Educational Symposium
5. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
6. Cosmetic Bootcamp Solidifies Lead as Investor Symposium for Aesthetic Medicine
7. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
8. AMIAs 31st Annual Symposium Opens in Chicago, IL
9. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
10. Aesthetic Extender Symposium, LLC Announces its Inaugural Event
11. New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... therapies for preterm labor , , FRIDAY,...ve found the switch that activates the uterine mus...that may lead to therapies for preterm labor. ,...tein IP on the surface of these uterine muscle cel...ncy. , But researchers from Dartmouth Medical ...
(Date:11/21/2008)...The University of Texas Health Science Center at H...nce in Aging Studies (TEXAS), to promote geriatric... million award from the Donald W. Reynolds Foundat...ill allow us to teach geriatric medicine principle... to practicing physicians. With the reach of Lyndo...
(Date:11/21/2008)... The Generic,Pharmaceu...atement today from,GPhA President and CEO Kathlee...FTC) roundtable on "Emerging Health Care Competiti...hat the FTC is conducting this roundtable demonstr...nsumers have access to safe and,affordable biogen...
(Date:11/21/2008)...swire-USNewswire/ -- The University of Texas M. ...a collaborative effort to eradicate breast cancer ...r Awareness and Research of the Americas today at ...ited States, and Vivian Fernandez de Torrijos, the...derson in the initiative are the U.S. Department o...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3
... feeling something is wrong with you and yet havin...k, 42 felt the same for almost the last 10 years b... multiple sclerosis (MS). MS is an disabling neur...by symptoms such as fatigue and limb weakness amon...
?????????????????????????????-Richard Bach For more than a week now, Noida, in Northern India, has been in the eye of the storm//. The events that unfolded revealed that two ‘local blisters’, Moninder
...est to detect infection of drug resistant forms of...n developed by Researchers at the Duke University ...ct drug-resistant viral strains even when present ...sts that detect drug-resistant strains only when p...
...ber of adults suffering severe heart problems due ...000 a study showed, //indicating the benefits of e...ssisted in better diagnosis and treatment, thus ex.... Congenital heart defects are capable of impedin...
Other Medicine News:Health News:In Search of Truth - 'Lie Detector 2Health News:In Search of Truth - 'Lie Detector 3Health News:In Search of Truth - 'Lie Detector 4
(Date:11/21/2008)...karia Holdings, Inc. today announced that it has b...ersey Technology Council (NJTC), a 1,200-member no...rt, networking opportunities, information and advo...karia earned the award based on criteria including...ision. , , "We are delighted that the New J...
(Date:11/20/2008)...T PHASE III TRIAL SHOW SIGNIFICANT, DECREASES...CTION, IN, FIBROMYALGI... Belgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz ...uronext Brussels: UCB),announced today positive p...,Phase III pivotal clinical trials of sodium oxyba...
(Date:11/20/2008)...- Radius Health ("Radius") announced today that it...d institutional financing round, increasing total ... amount raised since the company,s inception to $1... participated in the financing, led by MPM Bio IV ...Wellcome Trust, HealthCare Ventures, Oxford Biosci...
(Date:11/19/2008)...re-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mill...of,Takeda Pharmaceutical Company Limited (TSE: 40... 3 MONET1 trial evaluating motesanib (AMG 706) in,...he first-line treatment of,advanced non-small cel...ed,following a planned safety data review of 600 ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Schering Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings 1754 1AUDIO from Medialink and Kelloggs 3A The Jeans Dont Lie 1752 12007 Speakers Golf Tournament Sets 5 Year Fundraising Record 1750 12007 Speakers Golf Tournament Sets 5 Year Fundraising Record 1750 2APHA Urges President Bush to Reconsider Unfounded Basis for SCHIP Veto 1748 1APHA Urges President Bush to Reconsider Unfounded Basis for SCHIP Veto 1748 2
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone
...procedure follows the basic principle of a competi... between an unlabeled antigen and an labelled anti...ic antiserum . The amount of enzyme conjugate comp... the antibody is inversely proportional to the con...
...droepiandrosterone (5-Androstene-3-0L-17-one,Andro...ndrosterone, DHEA) is a steroid hormone present in...DHEA-S ELISA kit is based on the competition princ...mount of DHEA-S present in the sample and a fixed ...
...otensin Converting Enzyme (ACE), also known as Kin....15.1) with a molecular weight of at least 129,000...e polypeptide chain, a polysaccharide residue and ... types such as neuronal cells and renal proximal t...
Medicine Products: